Ditemukan 35461 dokumen yang sesuai dengan query :: Simpan CSV
Cervicitis is one of the Sexually Transmitted Infections (STIs). There is a correlation between socio-demographic development and migration with increase of the number of high-risk populations. WHO estimates there are 376 million new infections by 1 out of 4 STIs, such as chlamydia (127 million), gonorrhea (87 million), syphilis (6.3 million) and trichomoniasis (156 million). Gatot et al, showed that 11.9% of patients had cervicitis. Iskandar, et al, also showed the prevalence of cervical infections (chlamydia 9,3% and 1,2% gonorrhea). Based on the results of the SDKI, there had been an increasing trend in contraceptive use in Indonesia from 1991 to 2017. There was a statistically significant association between cervicitis and HPV infection. It will increase the risk of getting infected by HPV if cervicitis is left untreated. Additionally, a person with mucopurulent cervicitis symptoms has an increased risk of cervical cancer. This study aims to determine the relationship between the use of hormonal contraceptives and the incidence of cervicitis. This is a quantitative study with a cross sectional study design. This study used secondary data from the results of the VIA examination at the primary health care supervised by the Female Cancer Program (FcP) in DKI Jakarta in 2017-2019. The number of samples were 3563 people, who met the inclusion and exclusion criteria. This study used logistic regression to analyze the data. The prevalence of cervicitis in this study was 11.20%. There is a relationship between hormonal contraceptive use and the incidence of cervicitis which is statistically significant with p-value<0.0001. Thus, it is necessary to carry out periodic checks on women who use hormonal contraception to prevent cervicitis and cervical cancer.
High-risk Human Papillomavirus (HR-HPV) is the necessary factor for the development of cervical cancer. The use of hormonal contraception has been associated with HR-HPV risk infection. However, the existing study results are not conclusive. There is very limited relevant data available in Indonesia. Hence, this study is aimed to evaluate the association between the use of hormonal contraceptives and infection risk of HR-HPV based on data from a 2019 screening program held by Indonesian Cancer Foundation, Jakarta branch, in Jakarta. This is a case-control study using secondary data from a cervical cancer screening program in Jakarta during January-December 2019. The case group is subjects with positive HPV-DNA test results from Hybrid Capture 2. The control group is randomly selected from the screening participants with negative HPV-DNA test results, with a ratio with the case is 2:1, and frequency matched based on area of domicile. Data is analyzed using multivariate analysis, unconditional logistic regression. The number of case in this study is 172 and 344 subjects in the control group. The prevalence of HR-HPV infection from the whole screening program is 6,56%. Most study participants were not using any kind of contraception methods (62,79% cases; 49,13% control). The risk of HR-HPV is crude OR 0,64 (95% CI 0,39-1,04, p=0,06) and adjusted OR 0,97 (95% CI 0,53-1,79; p=0,93). in current user of hormonal contraceptives. Whilst the association in the past users of hormonal contraception prior the test is crude OR 0,55 (95%CI 0,37-0,83; p=0,002) and adjusted OR 0,53 (95% 0,34-0,82; p=0,005). There is no significant association between the current user of hormonal contraceptives and the risk of HR-HPV infection. On the other hand there is a significant negative association in the past user group.
Hypertension is one of diseases caused world health problems. The prevalence of hypertension is predicted will be increase. Hypertension in Indonesia are dominated by the female population. One of the risk factors caused hypertension is the use of hormonal contraception. This study aims to determine the association between the last birth hormonal contraception and the prevalence of hypertension. The research design was cross-sectional from January to June 2023 used the 2018 Riskesdas data. The exposed group was 45,178 respondents who used hormonal contraception and the unexposed group was 30,845 who did not use hormonal contraception. The results showed that there was a significant association between the use of hormonal contraception and the prevalence of hypertension after controlling for age and body mass index with AdjPR 1.10 (95% CI 1.06–1.12). This study also assessed the association between types of hormonal contraception including 3-month injection contraception with AdjPR value of 1.08 (95% CI 1.05-1.12); 1-month injectable contraception with AdjPR value of 0.99 (95% CI 0.93-1.05), implant contraceptive AdjPR 0.90 (95% CI 0.84-0.96), and contraceptive pill AdjPR 1.30 (95% CI 1.23-1.35). This is expected to illustrate the importance of choosing the right contraception to prevent the hypertension
